Journal
TRENDS IN MOLECULAR MEDICINE
Volume 17, Issue 8, Pages 452-462Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2011.03.003
Keywords
-
Funding
- MIT
- Whitehall Foundation
- Anonymous Foundation
- John Merck Scholar Program
- James H. Ferry Fund
- MIT Simons Initiative on Autism and the Brain
- NIH [MH091220-01]
Ask authors/readers for more resources
GABA (gamma-aminobutyric acid) is the major inhibitory neurotransmitter in the brain. The GABAergic system is indispensable for maintaining the balance between excitation and inhibition (E/I balance) required for normal neural circuit function. E/I imbalances that result from perturbations in the development of this system, ranging from the generation of inhibitory neurons to the formation of their synaptic connections, have been implicated in several neurodevelopmental disorders. In this review, we discuss how impairments at different stages in GABAergic development can lead to disease states. We also highlight recent studies which show that modulation of the GABAergic system can successfully reverse cognitive deficits in disease models and suggest that therapeutic strategies targeting the GABAergic system could be effective in treating neurodevelopmental disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available